Impact of clinical and molecular features on efficacy and outcome of patients with non-small cell lung cancer receiving second-line osimertinib

doi:10.1186/s12885-022-09683-1

	Impact of clinical and molecular features on efficacy and outcome of patients with non-small cell lung cancer receiving second-line osimertinib
	Jin, Ying 1,4,5,7; Lin, Chen 4,5; Shi, Xun 4,5; He, Qiong 4,5; Yan, Junrong 6; Yu, Xinmin 4,5; Chen, Ming 2,3,7
刊名	BMC CANCER
	2022-05-28
卷号	22
关键词	Clinical and molecular features Efficacy and outcome EGFR T790M mutation Non-small-cell lung cancer Osimertinib
DOI	10.1186/s12885-022-09683-1
通讯作者	Yu, Xinmin(yuxm@zjcc.org.cn) ; Chen, Ming(chenming@zjcc.org.cn)
英文摘要	Background Although with the impressive efficacy, several patients showed intrinsic resistance or an unsatisfactory response to Osimertinib. We aim to explore the impact of clinical and molecular features on efficacy and outcome of patients with EGFR T790M-mutation non-small cell lung cancer (NSCLC) receiving second-line Osimertinib. Methods Patients with EGFR T790M-mutant NSCLC who had acquired resistance to the first-generation EGFR TKI and then received Osimertinib as second-line treatment were included. Patients' demographic and clinical information, as well as molecular data were extracted from electronic medical records. The impact of clinical and molecular features on treatment response and patients' outcome were assessed. Results Among the 99 patients, 60 patients were tissue/pleural effusion T790M positive and 69 patients were plasma positive with a median PFS of 12.1 m and 9.9 m (P = 0.25), respectively. In addition, median PFS were similar between patients of plasma T790M + and patients of plasma T790M- (P = 0.94). The Pearson correlation test showed no significant relationship between plasma T790M abundance and PFS (r = 0.074, P = 0.546). In subgroup analyses, PFS was significantly improved in elder patients (P = 0.009) and patients with longer PFS to the first-generation EGFR TKI (P = 0.0008), while smokers tended to have worse PFS compared with non-smokers (P = 0.064). PARP1 mutant-type patients had a worse PFS compared with wild-type group (P = 0.0003). Patients with MYC amplification also had a worse PFS than MYC wild-type patients (P = 0.016). A significant PFS shrinkage was observed in TMB-High group as 6.77 m, compared with 19.10 m in TMB-Low group. The multivariate Cox analysis revealed that years >= 65 was an independent positive feature for PFS, while PARP1 mutation and TMB-H were negative features for PFS. Conclusion In conclusion, our findings in this study demonstrated that clinical and molecular features can be served as predictive biomarkers to stratify patients with EGFR T790M-mutant NSCLC receiving second-line Osimertinib.
资助项目	National Natural Science Foundation of China[81702248]
WOS关键词	OPEN-LABEL ; 1ST-LINE TREATMENT ; ACQUIRED-RESISTANCE ; CHEMOTHERAPY ; MULTICENTER ; GEFITINIB ; ERLOTINIB ; AFATINIB ; THERAPY
WOS研究方向	Oncology
语种	英语
出版者	BMC
WOS记录号	WOS:000801165100002
资助机构	National Natural Science Foundation of China
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/131119]
专题	中国科学院合肥物质科学研究院
通讯作者	Yu, Xinmin; Chen, Ming
作者单位	1.Zhejiang Key Lab Radiat Oncol, Hangzhou 310022, Zhejiang, Peoples R China 2.Sun Yat Sen Univ, Canc Ctr, Dept Radiat Oncol, Guangzhou 510060, Guangdong, Peoples R China 3.Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou 510060, Guangdong, Peoples R China 4.Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Hangzhou 310022, Zhejiang, Peoples R China 5.Chinese Acad Sci, Inst Basic Med & Canc IBMC, Hangzhou 310022, Zhejiang, Peoples R China 6.Nanjing Geneseeq Technol Inc, Med Dept, Nanjing 210000, Peoples R China 7.Soochow Univ, Affliated Hosp 2, Suzhou 215004, Jiangsu, Peoples R China
推荐引用方式 GB/T 7714	Jin, Ying,Lin, Chen,Shi, Xun,et al. Impact of clinical and molecular features on efficacy and outcome of patients with non-small cell lung cancer receiving second-line osimertinib[J]. BMC CANCER,2022,22.
APA	Jin, Ying.,Lin, Chen.,Shi, Xun.,He, Qiong.,Yan, Junrong.,...&Chen, Ming.(2022).Impact of clinical and molecular features on efficacy and outcome of patients with non-small cell lung cancer receiving second-line osimertinib.BMC CANCER,22.
MLA	Jin, Ying,et al."Impact of clinical and molecular features on efficacy and outcome of patients with non-small cell lung cancer receiving second-line osimertinib".BMC CANCER 22(2022).